Gene transcripts in primary tumors and CTCs
Introduction
Molecular characterization of primary tumors has already greatly contributed to the personalized treatment of cancer patients. High-throughput techniques have yielded knowledge of mutations or epigenomic changes in certain genes as well as prognostic and predictive models based on mRNA and miRNA expression profiles (1) (2) (3) (4) (5) (6) . Combined with classical tumor characteristics, these models are increasingly used to guide individualized treatment of patients, thereby aiming to avoid over-or under treatment. However, most of these prognostic and predictive models have been developed based on primary tumor tissue while metastases, rather than the primary tumor, determine the clinical outcome of cancer patients. It has been shown that metastases, which may develop several years after occurrence of the primary tumor and after prior systemic therapy in the adjuvant or neoadjuvant setting, can differ greatly from primary tumor tissue in terms of genetic characteristics (7) (8) (9) (10) (11) (12) (13) . It is therefore anticipated that molecular characterization of metastases will improve the currently available prognostic and predictive models. Taking biopsies from metastases in patients however, is an invasive and often painful procedure, and frequently impossible due to the lack of accessible lesions.
CTCs are tumor cells circulating in the peripheral blood of patients, shed from either the primary tumor or its metastases. A recently developed technology to quantify the number of CTCs in whole blood is the CellSearch™ CTC Test (Veridex LLC, Raritan, NJ). So far this is the only test which has been approved by the US Food and Drug Administration (FDA) (14) for the detection and enumeration of CTCs in metastatic prostate (15) , colorectal (16) and breast (17) cancer as an independent prognostic factor. After enrichment fluorescently labeled monoclonal antibodies specific for epithelial cells (CK-8/18/19), for leukocytes (CD45) and their nuclei with a nuclear staining dye (DAPI), and subsequently enumerated by a semi-automated fluorescence microscope.
In addition to enumeration, CTCs can also be isolated for molecular characterization. This may enable insight into the molecular biology of metastasis, the association of their molecular profiles with treatment outcomes, and reveal the presence of potential drugable targets. However, while EpCAM-based enrichment eliminates a large proportion of leukocytes (~4-log depletion), there are still considerable quantities of contaminating leukocytes (DAPI + /CD45 + ) present after this enrichment (18) . This contamination, together with the low frequency of CTCs, forms a challenge when aiming to characterize CTCs by very sensitive molecular methods such as PCR.
Despite these challenges, we have recently shown the feasibility of determining mRNA expression of epithelial-specific genes in CTC-enriched samples (18) . In addition to mRNA, another class of RNAs that increasingly attracts attention is the group of miRNAs. Each miRNA targets, on average, 200 mRNA transcripts by which miRNAs execute widespread control (19) . As might be expected based on these activities, altered expression of specific miRNA genes has already shown to contribute to the initiation and progression of cancer (20) (21) (22) . Therefore, miRNA-based cancer gene therapy offers the theoretical appeal of targeting multiple gene networks that are controlled by a single, aberrantly expressed miRNA (23) , making the profiling of miRNAs in cancer even more appealing, especially in the context of CTCs.
Here we describe the optimization of a method to perform both miRNA and mRNA expression analysis for multiple genes by real-time RT-PCR on as little as five CTCs isolated from 7.5 mL of blood, which is considered the clinically relevant cut off in patients with metastatic breast cancer (24) (25) (26) , in an environment containing excess quantities of up
Materials and Methods

Ethics statement
This study was approved by the Erasmus MC and local Institutional Review Boards (METC 2006-248) , and all donors and patients gave their written informed consent.
Breast tumor tissues and blood samples
From 61 patients with metastatic breast cancer, 2 x 7.5 mL blood samples were prospectively taken for CTC enumeration and isolation (for details see below) prior to initiation of systemic therapy for metastatic disease. From these 61 samples, 11 (18%) were excluded because of insufficient RNA quality and/or quantity (for details see below), rendering a total number of 50 patients eligible for further analysis. Netherlands, and 21 patients in the Oncology Center GZA St-Augustinus, Antwerpen, Belgium). For 8 out of 32 patients with at least 5 CTCs, primary tumor tissue containing at least 50% invasive epithelial tumor cells was available for RNA isolation (5 fresh frozen (FF) and 3 formalin-fixed paraffin-embedded (FFPE)). These 8 specimens were used for comparison of transcript levels between CTCs and corresponding primary tumors. Detailed clinico-pathological information for these 50 patients and the 8 matching primary tissues is given in Table 1 and in addition after dichotomization of patients at the for breast cancer clinically relevant level of 5 CTCs (24) (25) (26) These >200 nt aliquots were treated with DNAse I according the manufacturer's instruction.
Next, the 200 nt molecules present in the flow through were captured in a new RNeasy
Mini spin column in the presence of a final concentration of 60% EtOH and thus eluted separately from the >200 nt molecules. Using this approach consisting of two sequential filtrations with different ethanol concentrations, a 12 μL RNA fraction highly enriched in RNA species 200 nt and a 14 μL RNA fraction enriched in RNA species >200 nt could be obtained from the same sample.
Total RNA was isolated from FF tissue with RNA-Bee as described before (29) The generation of pre-amplified cDNA from total RNA from the FF and FFPE tissues and the >200 nt RNA fractions and subsequent Taqman-based qRT-PCR analysis, as well as the validation procedures to ensure homogeneous amplification, were performed as described before (18) .
To analyze miRNAs, a multiplex stem-loop cDNA approach was used essentially as described before (21) . In brief, up to 50 different RT primers (250 nM each) were pooled, concentrated for 60 min in a speed vacuum centrifuge at 50°C and resuspended in nuclease-free ddH2O to a final concentration of 50 nM each. The use of a specific primer with a hairpin structure during cDNA synthesis and mature miRNA specific detection probes precluded the detection of precursor miRNAs. Twenty-five to 50 ng of total RNA sample aliquots were reverse-transcribed in a final volume of 20 μL with a final concentration of 12.5 nM for each RT primer using the TaqMan MicroRNA for reverse transcription kit (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands (ABI)) according to the manufacturer's instructions and as described before (21) . were according to the "Megaplex RT reaction for TaqMan microRNA array" protocol from ABI, i.e., 40 cycles of 16°C for 2 min, 42°C for 1 min and 50°C for 1 sec, followed by a final incubation at 85°C for 5 min and a cool down to 4°C. Prior to PCR, half of the resulting multiplex cDNA was linearly pre-amplified in 15 cycles according to the manufacturer's instructions (TaqMan™ PreAmp from ABI) and as described previously for our multiplex gene expression studies(29). Before performing real-time PCRs for each of the miRNAs separately, RT samples were diluted in nuclease-free ddH2O and analyzed by real-time with cycling conditions according to the manufacturer's instructions.
To verify that the multiplex RT approach did not affect the quantification of specific miRNAs, all miRNA data were validated in a uniplex RT reaction. A pool consisting of RNA of different human breast tissues was included in each cDNA synthesis and preamplification run, and the resulting data were used to normalize for in-between experimental variations. In addition, all cDNA synthesis runs incorporated a minus RT reaction, which proved to be negative for all assays in this study. PCR efficiency, linearity, and the upper and lower detection limits of each of the individual miRNA assays were validated with a standard curve prepared of RNA from a pool of breast tumors. Negative controls included samples without reverse transcriptase and samples in which total RNA and cDNA was replaced with ddH2O. Quantitative values were obtained from the threshold cycle (Ct) at which the increase in TaqMan probe fluorescent signal associated with an exponential increase of PCR products reached the fixed threshold value of 0.08, which was in all cases at least 10-fold higher than the background signal.
Research. First selection of potentially CTC-specific mRNA and miRNA transcripts
The specifics of the used Taqman assays are given in Supplemental Table 2A for the   miRNAs and Supplemental Table 2B for Table   2A ).
For the mRNA transcripts, clinically relevant and potentially CTC-specific genes were selected in silico based on literature data and their reported low expression in white blood cells and higher expression in breast tumor tissues, according to the SAGE Genie qRT-PCR, that were potentially higher expressed in breast tumor cells relative to leukocytes (Supplemental Table 2B ).
Reference genes, data normalization and quality control
Unless stated otherwise, levels of HMBS, HPRT1 and GUSB were used to control sample loading and >200 nt RNA quality, as described previously(29). Bone marrow stromal cell antigen 1 (BST1) and protein tyrosine phosphatase receptor type C (PTPRC coding for CD45) were the control genes for leukocyte background and keratin 19 (KRT19) the control for CTC quantification(29).
Although appropriate reference molecules for miRNAs are still unknown for clinical breast cancer cells with a background of leukocytes, previous studies have shown that normalization on mean or median expression of all miRNAs measured in a sample can adequately reduce technical variation(31). Therefore, miRNA data of each individual sample were normalized on the median level of all miRNAs measured in that particular sample.
After verification of equal PCR efficiency for all assays, the relative expression levels were quantified by using the delta Ct method, which is the difference between the median Ct of the appropriate control genes and the Ct of the target gene. Only samples that were at the median Ct of all miRNAs and the median Ct of HMBS, HPRT1 and GUSB able to generate a signal within an arbitrarily chosen cut off set at 26 Ct were considered of sufficient quality and quantity to enter the study. By the use of this threshold, 11 out of our initial 61 patient CTC samples (18%) were excluded from further analysis.
Finally, all transcript data of the 50 CTC samples, 53 HBD controls and 8 primary tumors were normalized to the Ct of the appropriate reference set, after which, for each individual assay, the median Ct measured in CellSearch-enriched HBDs (n=31 for the mRNAs and The first purpose of this study was to establish a sensitive method to perform both mRNA and miRNA expression analysis of transcripts specific for CTCs, in samples often containing only a few CTCs in an environment of excess quantities of contaminating leukocytes.
To select the gene transcripts we used the approach described in detail in the Materials and Methods section, resulting in 43 putative breast CTC-specific miRNAs, 85 putative breast CTC-specific mRNAs and 5 control mRNAs. Our first challenge was to find a method that would enable us to measure both mRNAs and miRNAs in RNA isolated from as little as 5 CTCs (~50 pg total RNA), which is considered the clinically relevant cut point in patients with metastatic breast cancer (24) (25) (26) , in a reliable and quantitative manner. In this respect, as already described and tested for the mRNA assays (18) , any individual miRNA expression assay showing as a non-homogeneously amplified outlier in our tests should be treated with caution because the data may not be truly representative for the original sample. Therefore, our assay had to have a high sensitivity combined with a minimum number of non-homogeneously amplified miRNA and mRNA assays. To achieve this, we combined the already sensitive multiplex stem-loop cDNA approach with the Taqmanbased linear pre-amplification method, both from ABI. To validate the sensitivity and linear and homogeneous nature of this combined technique, we performed comparative tests between serially diluted non-amplified and multiplexed pre-amplified cDNA from total RNA of pooled primary breast tumors, as described before (18) . The homogeneity of amplification was set at a cut off of 2 Ct, i.e., for an assay to be considered homogeneously amplified, the number of cycles that were required after pre-amplification should be within a 2 Ct range of the number of cycles that were required for the non-amplified material. After adjusting for the median 15.5 Ct gain due to the pre-amplification procedure, data of 11 miRNA assays were outside this range (Table 2, lower part). After testing the 43 miRNAs in a multiplex cDNA PCR reaction in our patient cohort of 50 CTC samples, data of two additional miRNAs (hsa-miR-10b and RNU43) had to be discarded because they generated very poor amplification curves. Finally, the PCR efficiency of two of the remaining 30 assays were outside our set range of 75% to 125% (hsa-miR-135b, 135% and hsa-miR-452#, 73%) and were therefore also excluded from our final analyses (Table 2, 
column 6).
A resume of the results of these quality control experiments, which left us with 28 potentially breast CTC-specific miRNAs that could be measured reliably after our multiplexed cDNA followed by the pre-amplification procedure, are listed in Table 2 .
Finally, when implementing an assay into clinical diagnostics, it is important that data can be compared in-between qRT-PCR sessions. For our mRNA measurements we have previously shown that the data are reproducible using the pre-amplification procedure from ABI (18) . To certify that the miRNA data generated with these assays and the multiplex preamplification procedure were also reproducible in-between different qRT-PCR sessions, a control RNA sample consisting of 300 pg total RNA of a pool of breast tumors was included in each session. The relative expressions (average delta Ct ± 95% confidence interval) of the 28 miRNAs measured in this control sample in 28 independently performed multiplexed pre-amplified qRT-PCR sessions (Figure 1 ) with a median coefficient of variation (CV) at the absolute Ct level of 6%, ranging from 3% for hsa-miR-200a# to 15% for hsa-miR-184, illustrates the robustness of our method. The miRNA analyses showed that of the 446 miRNAs investigated, 28 miRNA transcripts could be measured reliably and linearly in a multiplex pre-amplification reaction with an anticipated over 10-fold (median 160-fold) higher expression in CTCs relative to bloodderived leukocytes (Table 2 and Supplemental Table 2A ). Of these 28 small RNAs, only one miRNA (hsa-miR-183) was higher expressed in the 32 samples that contained at least 5 CTCs compared with the 9 samples without detectable CTCs after the CellSearch procedure. At a FDR of 10%, 9 additional miRNA transcripts were more abundantly expressed in the preparations that contained at least 5 CTCs relative to whole blood preparations of HBDs prior to (n=14) or after (n=8) CellSearch enrichment (Table 3A) .
For the mRNA transcripts we used the approach described in detail before (18) . Of the thus in silico selected 85 putatively CTC-specific and/or for breast cancer clinically relevant genes (Supplemental Table 2B can be expected for a profiling study(36). In addition to these 55 mRNA transcripts, another 6 mRNA transcripts were more abundantly present in the 32 samples that contained at least 5 CTCs relative to the 14 whole blood samples from HBDs prior to CellSearch enrichment. Of the 55 mRNA transcripts, 14 were also more abundantly expressed in the 32 samples with at least 5 CTCs relative to the 9 enriched metastatic breast cancer blood samples without detectable CTCs. Finally, only 6 genes, including the 2 leukocyte control genes PTPRC (CD45) and BST1, were found to be significantly higher expressed in the 31
CellSearch-enriched HBD samples compared with the 32 patient samples with at least 5 CTCs (Table 3B ).
Research. It should be noted that the CTC counts are derived from one of the 2 aliquots of 7.5 mL blood samples that was processed with the CellSearch Epithelial Kit, while the other aliquot used for the molecular profiling was processed with the CellSearch Profiling Kit. This inevitably introduces stochastic variation between the tumor cell content in the two aliquots, which is more profound in the lower range of CTC counts. Discussion has also started about the actual number of isolated CTCs differing between the enumeration and profiling kit(37). The given cell counts can therefore only be used as a rough estimate for our molecular profile. Nevertheless, with 14 out of 55 mRNAs (25.4%) and only one (hsa-miR-183) out of 28 miRNAs (3.6%) higher expressed in the 32 samples that contained at least 5
CTCs compared with the 9 samples without detectable CTCs after the CellSearch enrichment procedure with the Epithelial Kit, it appears to be easier to discriminate between CTC-specific and leukocyte-derived mRNAs than between CTC-specific and leukocytederived miRNAs. Possibly, the detected miRNA transcripts were derived from cell fragments present in the blood of cancer patients without detectable intact CTCs. The fact that we were able to measure them might be associated with the remarkable stability of miRNA transcripts in blood(38). Indeed, the detection of an additional 9 out of 28 (32.1%) miRNAs that were higher expressed in breast cancer patients without detectable CTCs than in whole blood preparations of HBDs prior to (n=14) or after (n=8) CellSearch enrichment, compared to an additional 6 out of 55 (10.9%) for mRNAs, further supports this thought.
Unsupervised hierarchical clustering to identify clusters of patients according gene expression patterns
Next, unsupervised two-dimensional average linkage hierarchical cluster analysis(33) was performed to compare the gene expression profiles of our 50 patients. For this we used the 65 genes (55 mRNA and 10 miRNA transcripts) that were at a 10% FDR more abundantly expressed in CellSearch-enriched fractions of the 32 patients with at least 5 CTCs (Table   3B and One distinct gene cluster (gene cluster 3, correlation 0.35) was responsible for the association with the absence of CTCs, i.e., patient cluster 1. This 14-gene cluster holds, in addition to the previously identified CTC-specific genes KRT19, AGR2, S100A16 and KRT7, and as could be expected TACSTD1, the gene encoding EpCAM, the antigen that was used to enrich for CTCs, also the miRNAs hsa-miR-452 and hsa-miR-34a. Notably, the miRNA-cluster (gene cluster 4, correlation 0.20) containing hsa-miR-183, hsa-miR-184, hsa-miR-379 and hsa-miR-424 shows an expression pattern that appears to be inversely related to the "mutagenesis" gene cluster 2 -which includes ESR1-, the gene that encodes for the estrogen receptor (ER). This suggests that these miRNAs might be negatively regulated by ER or, vice-versa, that these miRNAs negatively regulate ER.
Although no specific category was identified by DAVID as significantly enriched in the last cluster (gene cluster 5, correlation 0.20), this cluster appears to be dominated by genes associated with cell cycle progression and proliferation such as DUSP4 (MKP2(45)), KIF11, KPNA2 and MKI67. Interestingly, a putative stem cell marker (ITGA6(46)) is also included in this last cluster. Of note is that half the patients with relatively high CTC-associated ESR1 levels expressed relatively low levels of TFF1. TFF1 is a gene under the control of ER. Perhaps, assessment of simultaneous TFF1 expression in CTCs might be able to identify a subset of patients with ER-positive CTCs with functionally active ER, which is more likely to respond to hormonal treatment(47).
To ascertain that the signals we generated were indeed tumor CTC specific, we also performed a clustering analysis with inclusion of the 14 full blood HBDs (FB-HBDs) from which we had data from both the mRNAs and miRNAs (Supplemental Figure 1) . These HBDs (marked in green below the cluster) indeed clustered closely together. Also the patients from patient cluster 1 (Figure 2 , and marked in red below the cluster diagram in Supplemental Figure 1 ), that were characterized by the lack of expression of epithelial marker genes, remain clustered together, next to the HBD cluster. This confirms that our molecular CTC profile is indeed able to discriminate between signals from leukocytes and epithelial specific signals from CTCs.
Research. 
Associations of the CTC molecular profile with primary tumor characteristics
For the association of the molecular profile with primary tumor characteristics, we continued with the 36 patients in patient clusters 2 through 4. These patients displayed a molecular CTC profile with very distinct patterns from the 14 patients in patient cluster 1, which were characterized by the lack of expression of epithelial marker genes. Detailed clinicopathological information of our patient cohort, subdivided in two groups (patient cluster 1 versus clusters 2 through 4) based on our molecular CTC-specific profile is given in Table   1 . There were no differences between both groups in terms of nodal status, tumor size, histological tumor type, grade, ER, PR and HER2 status. The only significant association with clinical information was that the patients of cluster 2 through 4 displayed a 2-fold higher rate of having both visceral and non-visceral metastases, as opposed to only visceral or non-visceral metastasis for the patients of cluster 1.
Almost identical results were obtained when the associations of primary tumor and patient characteristics were studied based on CTC count subdivided in two groups (patients with with less than 5 CTCs versus patients with at least 5 CTCs) (Supplemental Table 1 ).
Associations of gene transcripts measured in CTCs with current drug targets
Although we were not able to measure PGR transcripts reliably in the CTCs due to the relatively high PGR levels present in the contaminating leukocytes, we were able to measure the ESR1 and ERBB2 mRNA transcript levels, the genes for ER and HER2, respectively, in the CellSearch-enriched CTCs. ESR1 and ERBB2 expression levels measured in the 36 patients from cluster 2 through 4 with expression of epithelial marker genes, and compared with ER and HER2 status of the primary tumor as assessed by Figure 3 . For one of the patients whose primary tumor was assessed to be negative, a clearly positive ESR1 signal was detected in the CTCs (CTC087 in Figure 2 ) obtained at the time of metastatic disease 7 years after surgical removal of the primary tumor. Vice-versa and perhaps even more disturbing, in 11 out of 30 patients (37%) whose primary tumor was ER-positive, no detectable ESR1 transcript levels were measured in the CTCs obtained 1 to 149 months after primary surgery.
Thus, while according to the primary tumor characteristics these patients would have an indication for anti-hormonal treatment, no benefit might be expected from this therapy based on these CTC characteristics. However, due to the limited number of 4 of these 11 patients that were actually treated with anti-hormonal treatment, no conclusion can be drawn yet on the efficacy of hormonal treatment in these patients with ESR1-negative 
Comparison of gene profiles measured in the CTCs and corresponding primary tumors of metastatic breast cancer patients
We were able to retrieve 8 primary tumor tissues (3x FFPE and 5x FF) of our cohort of patients with at least 5 CTCs at the time of metastatic disease (median: 174, range 7-2,262 CTCs). We measured the 65 genes of our mRNA and miRNA panel in these tissues after adjusting levels measured in FFPE to those measured in FF. and MKI67 compared with the primary tumor (Figure 4) . Such differences between the primary tumor and CTCs isolated at the time of metastatic disease might proof clinically relevant and thus deserve further research.
Concluding remarks
By excluding genes with a relatively higher expression in leukocytes, our CTC-specific 65-gene set, consisting of 55 mRNAs and 10 miRNAs, is able to generate a huge amount of highly relevant CTC-specific data, even in the presence of a leukocyte background signal derived of leukocytes co-captured with CTCs when using the CellSearch procedure.
Although assessed in a relatively small series, we found discrepancies in several important factors such as ER, HER2 and other genes between primary tumor tissue and CTCs. This is not surprising given the time elapsing between primary tumor resection and CTC collection, which occurred at the diagnosis of metastatic disease, and the fact that several patients received prior adjuvant systemic therapy. The discrepancies in molecular characteristics between primary tumor tissue and CTCs clearly stress the importance of further studies on molecular characterization of CTCs.
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Research. after a 20-fold dilution, measured at 25, 6.25 and 1.56 ng in 43 individual miRNA-specific PCRs. For pool 2, only one sample of each dilution was used to measure all 43 miRNAs in a multiplex cDNA reaction, resulting, after an additional pre-amplification and dilution step, in a final input of 6, 1.25 and 0.38 pg for each individual miRNA-specific PCR reaction. For all miRNAs a minus RT sample at the second dilution was included that proved to be negative for all assays. The median reduction in the number of PCR cycles that was required to generate a signal after preamplification was 15.5. The homogeneity of amplification was therefore set at 15.5 ± 2 Ct. All assays that gained less than 13.5 or over 17.5 Ct after this multiplexed pre-amplification procedure were considered as not homogenously amplified. PCR efficiencies were calculated from the data thus generated with the 3 serially diluted samples with a PCR efficiency in-between 75% and 125% considered acceptable.
Research. Research. The expression levels of 28 miRNAs (Table 3A ) and 87 mRNAs (Table 3B) were measured in RNA isolated with the CellSearch Profiling Kit as described in the Materials and Methods section. To identify putative CTC-specific genes, transcript levels were compared in-between various groups with and without CTCs as established by the CellSearch Epithelial Kit in a separate 7.5 mL blood sample. The average expression ± standard error of the mean (SEM) is given for the number of samples indicated at the top in the Table. The 2-tailed Mann-Whitney U test was used to identify genes with a significantly different expression level in-between groups. To compensate for multiple testing, a FDR of 10% was applied on these statistics.
